Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

Kieuhoa T. Vo,Jennifer Gibney Michlitsch,Avanthi Tayi Shah,Janel Long-Boyle,Mi-Ok Kim,Clay Gustafson,Alejandro Sweet-Cordero,Katherine K. Matthay,Steven G. DuBois

Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

2018

Kieuhoa T. Vo
Jennifer Gibney Michlitsch
Avanthi Tayi Shah
Janel Long-Boyle
Mi-Ok Kim
Clay Gustafson
Alejandro Sweet-Cordero
Katherine K. Matthay
Steven G. DuBois

TPS10576Background: Sarcomas express pro-angiogenic factors that may represent therapeutic targets. Pazopanib, an oral multi-kinase inhibitor of VEGFR-(1-3), c-kit, and PDGFR, is FDA-approved for t...

Keywords:

Temozolomide
Pazopanib
Multicenter trial
Young adult
Physical therapy
Sarcoma
Maximum tolerated dose
Medicine
Irinotecan
Pharmacokinetics
Oncology
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations